Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
FibroGen ( (FGEN) ) just unveiled an announcement.
On August 18, 2025, FibroGen announced that it received regulatory approval from the China State Administration for Market Regulation for the sale of its subsidiary, FibroGen China, to AstraZeneca. This transaction, expected to close in the third quarter of 2025, involves the transfer of all equity interests and roxadustat assets in China to AstraZeneca, FibroGen’s long-time commercialization partner in the region. FibroGen retains rights to roxadustat in other markets, including the United States and Canada. The sale is part of FibroGen’s strategic operations, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (FGEN) stock is a Buy with a $250.00 price target. To see the full list of analyst forecasts on FibroGen stock, see the FGEN Stock Forecast page.
Spark’s Take on FGEN Stock
According to Spark, TipRanks’ AI Analyst, FGEN is a Neutral.
FibroGen’s overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues and persistent losses. While technical analysis indicates positive momentum, and the earnings call provided some strategic positives, these are overshadowed by the company’s financial instability and valuation concerns.
To see Spark’s full report on FGEN stock, click here.
More about FibroGen
FibroGen, Inc. is a biopharmaceutical company dedicated to developing innovative therapies in cancer biology and anemia. The company is known for its product roxadustat, which is approved for treating anemia in chronic kidney disease patients in various countries, including China, Europe, and Japan. FibroGen is also working on FG-3246, an antibody-drug conjugate for prostate cancer, and FG-3180, a related PET biomarker.
Average Trading Volume: 51,668
Technical Sentiment Signal: Sell
Current Market Cap: $38.4M
For an in-depth examination of FGEN stock, go to TipRanks’ Overview page.